Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
Condition(s):TuberculosisLast Updated:February 6, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):TuberculosisLast Updated:February 6, 2020Unknown status
Condition(s):COVID-19Last Updated:April 30, 2021Terminated
Condition(s):Heart FailureLast Updated:November 30, 2017Completed
Condition(s):Pulmonary HypertensionLast Updated:November 13, 2017Terminated
Condition(s):Type 2 DiabetesLast Updated:March 5, 2007Completed
Condition(s):Chronic Kidney Disease; Cardiovascular DiseaseLast Updated:October 1, 2019Completed
Condition(s):Gestational DiabetesLast Updated:May 22, 2020Completed
Condition(s):PeriodontitisLast Updated:March 15, 2013Completed
Condition(s):Glucose Intolerance; Impaired Insulin Secretion; Diabetes Mellitus Type 2Last Updated:March 26, 2012Unknown status
Condition(s):Knee InjuryLast Updated:May 30, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.